CVS Health (NYSE:CVS) Given Buy Rating at Tigress Financial

CVS Health (NYSE:CVS)‘s stock had its “buy” rating reiterated by stock analysts at Tigress Financial in a research report issued on Tuesday, December 26th.

CVS has been the subject of a number of other reports. Royal Bank of Canada initiated coverage on shares of CVS Health in a research note on Tuesday, September 19th. They issued an “outperform” rating and a $95.00 target price for the company. Jefferies Group boosted their target price on shares of CVS Health from $82.00 to $86.00 and gave the stock a “hold” rating in a research note on Friday, September 15th. Robert W. Baird reaffirmed a “hold” rating and issued a $77.00 target price on shares of CVS Health in a research note on Friday, October 27th. Mizuho set a $90.00 target price on shares of CVS Health and gave the stock a “buy” rating in a research note on Tuesday, October 24th. Finally, Needham & Company LLC raised shares of CVS Health from a “hold” rating to a “buy” rating and boosted their target price for the stock from $69.02 to $79.00 in a research note on Friday, November 10th. One analyst has rated the stock with a sell rating, nine have given a hold rating, twelve have issued a buy rating and two have issued a strong buy rating to the company. The stock presently has a consensus rating of “Buy” and a consensus price target of $86.66.

CVS Health (NYSE CVS) opened at $79.02 on Tuesday. CVS Health has a 1-year low of $66.45 and a 1-year high of $84.72. The stock has a market cap of $80,050.00, a PE ratio of 16.33, a P/E/G ratio of 1.38 and a beta of 0.90. The company has a current ratio of 1.05, a quick ratio of 0.55 and a debt-to-equity ratio of 0.67.

CVS Health (NYSE:CVS) last announced its quarterly earnings results on Monday, November 6th. The pharmacy operator reported $1.50 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.49 by $0.01. CVS Health had a net margin of 2.77% and a return on equity of 16.96%. The firm had revenue of $46.18 billion during the quarter, compared to the consensus estimate of $46.17 billion. During the same period last year, the firm posted $1.64 EPS. The firm’s quarterly revenue was up 3.5% on a year-over-year basis. equities analysts predict that CVS Health will post 5.9 earnings per share for the current fiscal year.

In related news, EVP Lisa Bisaccia sold 29,445 shares of the business’s stock in a transaction that occurred on Thursday, December 21st. The shares were sold at an average price of $75.00, for a total transaction of $2,208,375.00. Following the completion of the transaction, the executive vice president now owns 15,556 shares in the company, valued at $1,166,700. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. 0.61% of the stock is currently owned by insiders.

A number of hedge funds and other institutional investors have recently modified their holdings of the stock. Tiedemann Wealth Management LLC boosted its holdings in shares of CVS Health by 114.2% in the first quarter. Tiedemann Wealth Management LLC now owns 28,985 shares of the pharmacy operator’s stock valued at $2,275,000 after buying an additional 15,456 shares during the period. First National Trust Co. boosted its holdings in shares of CVS Health by 17.0% in the first quarter. First National Trust Co. now owns 22,304 shares of the pharmacy operator’s stock valued at $1,750,000 after buying an additional 3,242 shares during the period. Bahl & Gaynor Inc. boosted its holdings in shares of CVS Health by 1.1% in the first quarter. Bahl & Gaynor Inc. now owns 14,922 shares of the pharmacy operator’s stock valued at $1,171,000 after buying an additional 167 shares during the period. Oxford Asset Management acquired a new position in shares of CVS Health in the first quarter valued at approximately $3,995,000. Finally, Alambic Investment Management L.P. acquired a new position in shares of CVS Health in the first quarter valued at approximately $777,000. Hedge funds and other institutional investors own 81.62% of the company’s stock.

WARNING: “CVS Health (NYSE:CVS) Given Buy Rating at Tigress Financial” was originally published by Dispatch Tribunal and is the sole property of of Dispatch Tribunal. If you are accessing this article on another website, it was illegally copied and republished in violation of US and international trademark and copyright legislation. The original version of this article can be read at https://www.dispatchtribunal.com/2018/01/12/cvs-health-cvs-rating-reiterated-by-tigress-financial.html.

CVS Health Company Profile

CVS Health Corporation, together with its subsidiaries, is an integrated pharmacy healthcare company. The Company provides pharmacy care for the senior community through Omnicare, Inc (Omnicare) and Omnicare’s long-term care (LTC) operations, which include distribution of pharmaceuticals, related pharmacy consulting and other ancillary services to chronic care facilities and other care settings.

Analyst Recommendations for CVS Health (NYSE:CVS)

Receive News & Ratings for CVS Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CVS Health and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply